Market Cap 251.77M
Revenue (ttm) 351.41M
Net Income (ttm) 880,000.00
EPS (ttm) N/A
PE Ratio 40.25
Forward PE 6.71
Profit Margin 0.25%
Debt to Equity Ratio -1.25
Volume 822,400
Avg Vol 1,418,398
Day's Range N/A - N/A
Shares Out 162.43M
Stochastic %K 47%
Beta 0.30
Analysts Hold
Price Target $0.92

Company Profile

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA na...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 617 621 7722
Fax: 617 494 0480
Address:
100 Summer Street, Suite 2300, Boston, United States
TeeMan123
TeeMan123 Oct. 7 at 1:09 AM
$IRWD every 2-bit company with an early stage asset that has shown any glimpse of promise is going parabolic despite years and years of additional trials, today it was IVVD, SPRB, PALI.. meanwhile we have a derisked P3 asset that was bought for 1bln in cash and we languish in this bull biotech market not even remotely close to valued at 1bln and we are not even talking about linzess…. I suppose it’s a good sign that the review process hasn’t completed yet? Maybe that means lots of options being considered? But the more we wait, the more concerned I get mgmt will inevitably do something stupid given their track record. GET SOMETHING DONE!!!
0 · Reply
VSTN
VSTN Oct. 7 at 1:07 AM
$IRWD It’s all good. 2 weeks ago we were complaining she was below $1.3…..
0 · Reply
ASKING7
ASKING7 Oct. 7 at 12:22 AM
$IRWD the games goes on
0 · Reply
VSTN
VSTN Oct. 6 at 6:37 PM
$IRWD Let’s all buy 1000 shares today and drive it up
1 · Reply
LakeAccess
LakeAccess Oct. 6 at 6:23 PM
$IRWD Papa needs some dry powder - let’s go!
0 · Reply
buymoremakemore
buymoremakemore Oct. 6 at 2:45 PM
$IRWD C’mon guys. There are two stocks I really want to get into. Hopefully not much longer
1 · Reply
juneleeyo
juneleeyo Oct. 5 at 3:12 PM
$IRWD Goldman Sachs-Four possible strategic outcomes expected: 1. Sell the entire IRWD company — with an upfront cash payment per share plus CVR 2. Sell LINZESS to AbbVie and form a partnership (with upfront cash payment) with AbbVie to co-develop apraglutide (Apra). AbbVie is deeply interested in GI Franchise / SBS market. 3. Sell LINZESS only to AbbVie and independently run the apraglutide Phase 3 trial 4. Secure a partnership with another company that includes a milestone payment (~$250–500 million upfront) and a co-development agreement for the Phase 3 apraglutide trial I think #1 or #2 makes the most business sense for Goldman Sachs and IRWD. #3 and #4 are the next best following #1 and #2. Each of 4 scenarios is value generating.
2 · Reply
DipSensor
DipSensor Oct. 5 at 8:17 AM
$IRWD Pharmaceutical development. High volatility on regulatory updates. No technical pattern established. Speculative only.
0 · Reply
Solaf
Solaf Oct. 5 at 6:55 AM
$IRWD I am not sure about patent extension but as some bright minds previously indicated here it will be a big step towards becoming OTC and challenging Miralax market share
0 · Reply
juneleeyo
juneleeyo Oct. 5 at 1:33 AM
$IRWD If the P3 study of Linzess on ped (2-5 yo) finished on 9/2/2025, when would you expect P3 trial data release? How long does the data analysis take? If + results, it would be approved by FDA to use in Pediatric population for functional constipation and potentially extend the patent well beyond 2030. https://www.tipranks.com/news/company-announcements/abbvies-phase-3-pediatric-constipation-study-completes-potential-market-impact-looms
0 · Reply
Latest News on IRWD
Ironwood Pharmaceuticals Reports First Quarter 2025 Results

May 7, 2025, 7:05 AM EDT - 5 months ago

Ironwood Pharmaceuticals Reports First Quarter 2025 Results


Ironwood Pharmaceuticals Reports Third Quarter 2024 Results

Nov 7, 2024, 7:00 AM EST - 11 months ago

Ironwood Pharmaceuticals Reports Third Quarter 2024 Results


Ironwood Pharmaceuticals Reports Second Quarter 2024 Results

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Ironwood Pharmaceuticals Reports Second Quarter 2024 Results


Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC

Jun 20, 2024, 1:00 PM EDT - 1 year ago

Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC


TeeMan123
TeeMan123 Oct. 7 at 1:09 AM
$IRWD every 2-bit company with an early stage asset that has shown any glimpse of promise is going parabolic despite years and years of additional trials, today it was IVVD, SPRB, PALI.. meanwhile we have a derisked P3 asset that was bought for 1bln in cash and we languish in this bull biotech market not even remotely close to valued at 1bln and we are not even talking about linzess…. I suppose it’s a good sign that the review process hasn’t completed yet? Maybe that means lots of options being considered? But the more we wait, the more concerned I get mgmt will inevitably do something stupid given their track record. GET SOMETHING DONE!!!
0 · Reply
VSTN
VSTN Oct. 7 at 1:07 AM
$IRWD It’s all good. 2 weeks ago we were complaining she was below $1.3…..
0 · Reply
ASKING7
ASKING7 Oct. 7 at 12:22 AM
$IRWD the games goes on
0 · Reply
VSTN
VSTN Oct. 6 at 6:37 PM
$IRWD Let’s all buy 1000 shares today and drive it up
1 · Reply
LakeAccess
LakeAccess Oct. 6 at 6:23 PM
$IRWD Papa needs some dry powder - let’s go!
0 · Reply
buymoremakemore
buymoremakemore Oct. 6 at 2:45 PM
$IRWD C’mon guys. There are two stocks I really want to get into. Hopefully not much longer
1 · Reply
juneleeyo
juneleeyo Oct. 5 at 3:12 PM
$IRWD Goldman Sachs-Four possible strategic outcomes expected: 1. Sell the entire IRWD company — with an upfront cash payment per share plus CVR 2. Sell LINZESS to AbbVie and form a partnership (with upfront cash payment) with AbbVie to co-develop apraglutide (Apra). AbbVie is deeply interested in GI Franchise / SBS market. 3. Sell LINZESS only to AbbVie and independently run the apraglutide Phase 3 trial 4. Secure a partnership with another company that includes a milestone payment (~$250–500 million upfront) and a co-development agreement for the Phase 3 apraglutide trial I think #1 or #2 makes the most business sense for Goldman Sachs and IRWD. #3 and #4 are the next best following #1 and #2. Each of 4 scenarios is value generating.
2 · Reply
DipSensor
DipSensor Oct. 5 at 8:17 AM
$IRWD Pharmaceutical development. High volatility on regulatory updates. No technical pattern established. Speculative only.
0 · Reply
Solaf
Solaf Oct. 5 at 6:55 AM
$IRWD I am not sure about patent extension but as some bright minds previously indicated here it will be a big step towards becoming OTC and challenging Miralax market share
0 · Reply
juneleeyo
juneleeyo Oct. 5 at 1:33 AM
$IRWD If the P3 study of Linzess on ped (2-5 yo) finished on 9/2/2025, when would you expect P3 trial data release? How long does the data analysis take? If + results, it would be approved by FDA to use in Pediatric population for functional constipation and potentially extend the patent well beyond 2030. https://www.tipranks.com/news/company-announcements/abbvies-phase-3-pediatric-constipation-study-completes-potential-market-impact-looms
0 · Reply
Bio_Invest101
Bio_Invest101 Oct. 3 at 8:42 PM
$IRWD In 3 months we gained 118% but somehow the MM wanted to make us feel bad since we broke up $1.73. I am very happy and proud of all serious longs for not being a whiner today since eSP failed to hold at new high $1.7 ! But We’re winning so be happy and proud that you didn’t fall for the mind gymnastics games that the MM put down for us. As I said b4 it’s getting harder and harder for MM to get shares any more so they have to raise the bars ( baites) higher constantly to get some people to sell. If $1.73 didn’t stand then they beat it down 20% to scare and squeeze you. They wanted you to second guess that someone must know something but only we retails don’t know. This was all done without any news, good or bad ones. Worth of a small Friday celebration for reaching new 6-month high at $1.73 today. Next new YTD high at $4.5 I BELIEVE we just get started on first base. Have a nice weekend.
0 · Reply
VSTN
VSTN Oct. 3 at 8:33 PM
$IRWD Could have been much worse.
0 · Reply
buymoremakemore
buymoremakemore Oct. 3 at 7:58 PM
$IRWD nice recovery!
0 · Reply
revueltoL
revueltoL Oct. 3 at 5:51 PM
$IRWD Rome wasn’t built in a day…building up to anticipation #3 😀
0 · Reply
noturfinancrbro
noturfinancrbro Oct. 3 at 5:47 PM
$IRWD thank you for the dip 😋
0 · Reply
Nibbler
Nibbler Oct. 3 at 5:27 PM
$IRWD Getting close to a 20% intraday drop
0 · Reply
VSTN
VSTN Oct. 3 at 5:21 PM
$IRWD Well, if was fun while it lasted.
0 · Reply
TeeMan123
TeeMan123 Oct. 3 at 5:16 PM
$IRWD I reiterate, Mr Market is rewarding any company with even a remote possibility of having an effective drug that is right sizing their balance sheet.. mgmt must not miss this opportunity, close out the strategic exercise asap please
0 · Reply
buysellrepeat
buysellrepeat Oct. 3 at 5:11 PM
1 · Reply
ASKING7
ASKING7 Oct. 3 at 4:40 PM
$IRWD Rejected at $1.7, but we shall retest it again soon
0 · Reply
mkmike396
mkmike396 Oct. 3 at 4:36 PM
$IRWD we know it won’t keep the highs for long, all that’s important is the highs are higher
0 · Reply
Bio_Invest101
Bio_Invest101 Oct. 3 at 2:13 PM
$IRWD Anybody grew up fishing with your old man? This is the MM fishing. Have fun and say NO to Debbie the Downer ! https://x.com/fishingfunfun/status/1348918137383649282?s=46&t=0dxFfv8Iw4yOBhPO0oZagA
1 · Reply